| First author . | Publication year . | Treatment . | Percentage with rectal NG cured (no. cured/ no. tested) . | Setting and country . | Gender of participantsa . | Diagnostic assay . | Median follow up (days) . | Side effects % (no./total)b . |
|---|---|---|---|---|---|---|---|---|
| Baddour25 | 1989 | CFX 1 g AMX 3 g+PROB 1 g | 98.1 (53/54) 97.6 (41/42) | STI Clinic, USA | F | Culture | 5.5 | CFX 1 g N: 3.8% (9/235) V: 3.4% (8/235) D: 1.3% (3/235) AMX 3 g+PROB 1 g N: 2.2% (5/231) V: 0.9% (2/231) D: 3.5% (8/231) |
| Baddour24 | 1992 | AMP 1 g+SUL 0.5 g+PROB 1 g CRO 250 mg | 100.0 (8/8) 100.0 (7/7) | STI Clinic, USA | Both | Culture | 5.5 | AMP 1 g+SUL 0.5 g+PROB 1 g, NA CRO 250 mg N: NA V: NA D: 3.1% (3/97) |
| Batteiger26 | 1985 | AMP 3.5 g+PROB 1 g | 100.0 (12/12) | STI Clinic, USA | F | Culture | 10.5 | |
| Black27 | 1989 | OFX 400 mg AMX 3 g+PROB 1 g | 100.0 (13/13) 100.0 (17/17) | STI Clinic, USA | F | Culture | 7.5 | |
| Cavenee28 | 1993 | CRO 250 mg SPT 2 g AMX 3 g+PROB 1 g | 95.5 (21/22) 100.0 (19/19) 85.2 (23/27) | Hospital, USA | F (pregnant females only) | Culture | 7 | CRO 250 mg, NA SPT 2 g, NA AMX 3 g+PROB 1 g N: NA V: 1.2% (1/84) D: NA |
| Chen19 | 2019 | CRO 500 mg+AZM 1000 mg SOL 1000 mg | 100.0 (12/12) 83.3 (5/6) | STI Clinic, USA and Australia | Both | Culture+NAAT | 7 | CRO 500 mg+AZM 1000 mg N: 11.5% (15/131) V: 0.0% (0/131) D: 15.3% (20/131) SOL 1000 mg N: 20.8% (27/130) V: 2.3% (3/130) D: 23.8% (31/130) |
| Collier29 | 1984 | CRO 125 mg SPT 2 g | 100.0 (23/23) 100.0 (12/12) | STI Clinic, USA | F | Culture | 6 | |
| Covino30 | 1990 | OFX 400 mg CRO 250 mg | 100.0 (2/2) 83.3 (5/6) | STI Clinic, USA | F | Culture | 6 | |
| Covino31 | 1993 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 7 | |
| Das68 | 1989 | CFX 1 g AMP 3 g+PROB 1 g | 100.0 (7/7) 100.0 (4/4) | Setting and country not stated | Both | Culture | 7 | |
| Dixon59 | 1986 | CRO 500 mg PPEN 1.5 g+BPEN 300 mg | 100.0 (1/1) 80.0 (4/5) | STI Clinic, UK | Both | Culture | 16 | |
| Dubois69 | 1990 | AMX 3 g+PROB 1 g | 100.0 (2/2) | Setting and country not stated | F | Culture | 5.5 | AMX 3 g+PROB 1 g N: 3.9% (3/77) V: 2.6% (2/77) D: 1.3% (1/77) |
| Edwards32 | 1984 | AMX 3 g+PROB 1 g | 100.0 (7/7) | STI Clinic, USA | Both | Culture | 7 | |
| Forstrom64 | 1972 | PPEN 2.4 MU | 100.0 (14/14) | Hospital, Finland | F | Culture | 7 | |
| Forstrom63 | 1974 | AMP 2000 mg+PROB 1 g | 92.9 (13/14) | Hospital, Finland | F | Culture | 7 | |
| Gottlieb33 | 1985 | ATM 1 g SPT 2 g | 100.0 (3/3) 100.0 (6/6) | STI Clinic, USA | Both | Culture | 6 | |
| Gottlieb34 | 1986 | CFX 1 g+PROB 1 g CFX 1 g AMX 3 g+PROB 1 g | 100.0 (6/6) 66.7 (4/6) 66.7 (2/3) | STI Clinic, USA | M | Culture | 6 | |
| Greaves35 | 1983 | FOX 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 95.7 (45/47) 97.4 (38/39) | STI Clinic, USA | Both | Culture | 8 | |
| Handsfield71 | 1981 | CRO 125 mg CRO 250 mg CRO 500 mg | 100.0 (5/5) 100.0 (3/3) 100.0 (2/2) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield70 | 1983 | CRO 125 mg CRO 250 mg SPT 2 g | 100.0 (8/8) 100.0 (6/6) 95.5 (21/22) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield37 | 1991 | CFM 400 mg CFM 800 mg CRO 250 mg | 100.0 (10/10) 100.0 (6/6) 100.0 (6/6) | STI Clinic, USA | F | Culture | 6.5 | CFM 400 mg N: 0.9% (1/107) V: NA D: 7.5% (8/107) CFM 800 mg N: 4.4% (4/91) V: NA D: 13.2% (12/91) CRO 250 mg N: 0.0% (0/104) V: NA D: 3.8% (4/104) |
| Handsfield36 | 1994 | AZM 2 g CRO 250 mg | 96.3 (26/27) 100.0 (17/17) | STI Clinic, USA | Both | Culture | 7 | AZM 2 g N: 19.5% (84/431) V: 7.0% (30/431) D: 13.7% (59/431) CRO 250 mg, NA |
| Hook39 | 1986 | SPT 2 g | 100.0 (33/33) | STI Clinic, USA | M | Culture | 5.5 | |
| Hook38 | 1993 | CIP 250 mg CRO 250 mg | 100.0 (20/20) 100.0 (21/21) | STI Clinic, USA | F | Culture | 7 | |
| Hook72 | 1997 | CFM 400 mg | 100.0 (3/3) | Hospital, country not stated | M | Culture | 7.5 | |
| Hook17 | 2019 | CRO 250 mg DEL 900 mg | 100.0 (13/13) 82.6 (19/23) | Setting not stated, USA | Both | Culture+NAAT | 7 | CRO 250 mg N: 1.3% (2/154) V: 0.6% (1/154) D: 7.1% (11/154) DEL 900 mg N: 7.9% (24/304) V: 2.6% (8/304) D: 31.9% (97/304) |
| Jones40 | 1991 | CTX 500 mg CRO 250 mg | 100.0 (5/5) 100.0 (4/4) | STI Clinic, USA | Both | Culture | 5.5 | CTX 500 mg, NA CRO 250 mg N: 1.7% (1/58) V: NA D: 3.4% (2/58) |
| Judson73 | 1983 | CRO 250 mg PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (10/10) 100.0 (11/11) | Setting and country not stated | F | Culture | 5.5 | |
| Judson41 | 1985 | CRO 125 mg SPT 2 g | 100.0 (52/52) 100.0 (9/9) | STI Clinic, USA | M | Culture | 6 | |
| Kaplowitz42 | 1987 | AMP 3.5 g+PROB 1 g | 87.5 (7/8) | STI Clinic, USA | Both | Culture | 5 | AMP 3.5 g+PROB 1 g N: 2.7% (2/75) V: 1.3% (1/75) D: NA |
| Kirkcaldy43 | 2014 | GEN 240 mg+AZM 2 g GEM 320 mg+AZM 2 g | 100.0 (1/1) 100.0 (5/5) | STI Clinic, USA | Both | Culture | 13.5 | GEN 240 mg+AZM 2 g N: 27.7% (56/202) V: 7.4% (15/202) D: 19.3% (39/202) GEM 320 mg+AZM 2 g N: 37.2% (74/199) V: 5.0% (10/199) D: 23.1% (46/199) |
| Lossick44 | 1982 | CFX 1.5 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 97.1 (34/35) 85.2 (23/27) | STI Clinic, USA | F | Culture | 5 | |
| McCormack45 | 1993 | CTX 500 mg CRO 250 mg | 100.0 (16/16) 100.0 (19/19) | Setting not stated, USA | Both | Culture | 5.5 | |
| Mogabgab46 | 1994 | CTX 500 mg CRO 250 mg | 100.0 (3/3) 100.0 (3/3) | STI Clinic, USA | Both | Culture | 5.5 | |
| Mohanty60 | 1988 | ATM 1 g | 100.0 (8/8) | Hospital, UK | Both | Culture | 14 | |
| Mroczkowski47 | 1997 | CFM 400 mg | 97.4 (37/38) | STI Clinic, USA | F | Culture | 7.5 | CFM 400 mg N: 2.1% (4/189) V: 1.1% (2/189) D: 0.5% (1/189) |
| Obaid48 | 1983 | PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Pabst49 | 1989 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 8.5 | |
| Raad58 | 1988 | PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) | STI Clinic, USA and Peru | Both | Culture | 5 | |
| Ramus50 | 2001 | CRO 125 mg CFM 400 mg | 100.0 (23/23) 100.0 (16/16) | Hospital, USA | F (pregnant females only) | Culture | 7 | |
| Rob66 | 2019 | GEN 240 mg+AZM 2 g CRO 500 mg+AZM 2 g | 100.0 (40/40) 100.0 (38/38) | Hospital, Czech Republic | Both | NAAT | 10 | GEN 240 mg+AZM 2 g N: 19.4% (14/72) V: 0.0% (0/72) D: 23.6% (17/72) CRO 500 mg+AZM 2 g N: 26.8% (19/71) V: 1.4% (1/71) D: 26.8% (19/71) |
| Romanowski65 | 1984 | AMP 3.5 g+PROB 1 g | 100.0 (23/23) | Setting not stated, Canada | Both | Culture | 5.5 | |
| Ross61 | 2019 | GEN 240 mg+AZM 1 g CRO 500 mg+AZM 1 g | 89.9 (107/119) 97.8 (134/137) | STI Clinic, UK | Both | Culture+NAAT | 14 | GEN 240 mg+AZM 1 g N: 13.8% (41/298) V: 4.0% (12/298) D: NA CRO 500 mg+AZM 1 g N: 11.9% (38/320) V: 0.9% (3/320) D: NA |
| Scott62 | 1987 | CIP 250 mg AMP 500 mg q6h for 5/7+PROB 1 g | 100.0 (3/3) 100.0 (3/3) | Hospital, UK | M | Culture | 14 | |
| Simpson51 | 1981 | PPEN 4.8 MU+PROB 1 g CTX 1 g | 100.0 (9/9) 100.0 (9/9) | STI Clinic, USA | Both | Culture | 5 | |
| Simpson52 | 1982 | PIP 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Sinanian53 | 1973 | SPT 4 g TET 9 g | 98.2 (54/55) 93.0 (53/57) | STI Clinic, USA | F | Culture | 7 | SPT 4 g, NA TET 9 g N: 3.0% (6/198) V: NA D: NA |
| Slutkin54 | 1982 | PPEN 4.8 MU+PROB 1 g | 87.5 (14/16) | STI Clinic, USA | Both | Culture | 6 | |
| Smith55 | 1993 | CRO 250 mg | 100.0 (24/24) | STI Clinic, USA | F | Culture | 7 | CRO 250 mg N: 0.3% (1/380) V: NA D: 0.5% (2/380) |
| Stolz67 | 1984 | CTX 1 g CFX 1.5 g | 100.0 (103/103) 92.2 (71/77) | Setting not stated, The Netherlands | Both | Culture | 10.5 | CTX 1 g N: 0.3% (2/590) V: NA D: NA CFX 1.5 g N: 0.3% (2/647) V: NA D: NA |
| Stoner56 | 2001 | GAT 400 mg GAT 600 mg OFX 400 mg | 100.0 (20/20) 100.0 (16/16) 100.0 (7/7) | Setting not stated, USA | F | Culture | 7 | GAT 400 mg N: 8.1% (24/295) V: 0.7% (2/295) D: 2.0% (6/295) GAT 600 mg N: 10.7% (31/291) V: 1.7% (5/291) D: 3.4% (10/291) OFX 400 mg N: 4.2% (6/142) V: 1.4% (2/142) D: 2.8% (4/142) |
| Taylor18 | 2018 | GEP 1500 mg GEP 3000 mg | 100.0 (1/1) 100.0 (2/2) | Setting not stated, USA and UK | M | Culture+NAAT | 6 | GEP 1500 mg N: 5.8% (3/52) V: NA D: 17.3% (9/52) GEP 3000 mg N: 20.8% (11/53) V: NA D: 35.8% (19/53) |
| Taylor20 | 2018 | ZOL 2 g ZOL 3 g CRO 500 mg | 100.0 (4/4) 100.0 (6/6) 100.0 (3/3) | STI Clinic, USA | Both | Culture+NAAT | 6 | |
| Thorpe57 | 1996 | CFX 1000 mg CIP 500 mg | 96.8 (30/31) 100.0 (26/26) | STI Clinic, USA and Puerto Rico | Both | Culture | 6 |
| First author . | Publication year . | Treatment . | Percentage with rectal NG cured (no. cured/ no. tested) . | Setting and country . | Gender of participantsa . | Diagnostic assay . | Median follow up (days) . | Side effects % (no./total)b . |
|---|---|---|---|---|---|---|---|---|
| Baddour25 | 1989 | CFX 1 g AMX 3 g+PROB 1 g | 98.1 (53/54) 97.6 (41/42) | STI Clinic, USA | F | Culture | 5.5 | CFX 1 g N: 3.8% (9/235) V: 3.4% (8/235) D: 1.3% (3/235) AMX 3 g+PROB 1 g N: 2.2% (5/231) V: 0.9% (2/231) D: 3.5% (8/231) |
| Baddour24 | 1992 | AMP 1 g+SUL 0.5 g+PROB 1 g CRO 250 mg | 100.0 (8/8) 100.0 (7/7) | STI Clinic, USA | Both | Culture | 5.5 | AMP 1 g+SUL 0.5 g+PROB 1 g, NA CRO 250 mg N: NA V: NA D: 3.1% (3/97) |
| Batteiger26 | 1985 | AMP 3.5 g+PROB 1 g | 100.0 (12/12) | STI Clinic, USA | F | Culture | 10.5 | |
| Black27 | 1989 | OFX 400 mg AMX 3 g+PROB 1 g | 100.0 (13/13) 100.0 (17/17) | STI Clinic, USA | F | Culture | 7.5 | |
| Cavenee28 | 1993 | CRO 250 mg SPT 2 g AMX 3 g+PROB 1 g | 95.5 (21/22) 100.0 (19/19) 85.2 (23/27) | Hospital, USA | F (pregnant females only) | Culture | 7 | CRO 250 mg, NA SPT 2 g, NA AMX 3 g+PROB 1 g N: NA V: 1.2% (1/84) D: NA |
| Chen19 | 2019 | CRO 500 mg+AZM 1000 mg SOL 1000 mg | 100.0 (12/12) 83.3 (5/6) | STI Clinic, USA and Australia | Both | Culture+NAAT | 7 | CRO 500 mg+AZM 1000 mg N: 11.5% (15/131) V: 0.0% (0/131) D: 15.3% (20/131) SOL 1000 mg N: 20.8% (27/130) V: 2.3% (3/130) D: 23.8% (31/130) |
| Collier29 | 1984 | CRO 125 mg SPT 2 g | 100.0 (23/23) 100.0 (12/12) | STI Clinic, USA | F | Culture | 6 | |
| Covino30 | 1990 | OFX 400 mg CRO 250 mg | 100.0 (2/2) 83.3 (5/6) | STI Clinic, USA | F | Culture | 6 | |
| Covino31 | 1993 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 7 | |
| Das68 | 1989 | CFX 1 g AMP 3 g+PROB 1 g | 100.0 (7/7) 100.0 (4/4) | Setting and country not stated | Both | Culture | 7 | |
| Dixon59 | 1986 | CRO 500 mg PPEN 1.5 g+BPEN 300 mg | 100.0 (1/1) 80.0 (4/5) | STI Clinic, UK | Both | Culture | 16 | |
| Dubois69 | 1990 | AMX 3 g+PROB 1 g | 100.0 (2/2) | Setting and country not stated | F | Culture | 5.5 | AMX 3 g+PROB 1 g N: 3.9% (3/77) V: 2.6% (2/77) D: 1.3% (1/77) |
| Edwards32 | 1984 | AMX 3 g+PROB 1 g | 100.0 (7/7) | STI Clinic, USA | Both | Culture | 7 | |
| Forstrom64 | 1972 | PPEN 2.4 MU | 100.0 (14/14) | Hospital, Finland | F | Culture | 7 | |
| Forstrom63 | 1974 | AMP 2000 mg+PROB 1 g | 92.9 (13/14) | Hospital, Finland | F | Culture | 7 | |
| Gottlieb33 | 1985 | ATM 1 g SPT 2 g | 100.0 (3/3) 100.0 (6/6) | STI Clinic, USA | Both | Culture | 6 | |
| Gottlieb34 | 1986 | CFX 1 g+PROB 1 g CFX 1 g AMX 3 g+PROB 1 g | 100.0 (6/6) 66.7 (4/6) 66.7 (2/3) | STI Clinic, USA | M | Culture | 6 | |
| Greaves35 | 1983 | FOX 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 95.7 (45/47) 97.4 (38/39) | STI Clinic, USA | Both | Culture | 8 | |
| Handsfield71 | 1981 | CRO 125 mg CRO 250 mg CRO 500 mg | 100.0 (5/5) 100.0 (3/3) 100.0 (2/2) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield70 | 1983 | CRO 125 mg CRO 250 mg SPT 2 g | 100.0 (8/8) 100.0 (6/6) 95.5 (21/22) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield37 | 1991 | CFM 400 mg CFM 800 mg CRO 250 mg | 100.0 (10/10) 100.0 (6/6) 100.0 (6/6) | STI Clinic, USA | F | Culture | 6.5 | CFM 400 mg N: 0.9% (1/107) V: NA D: 7.5% (8/107) CFM 800 mg N: 4.4% (4/91) V: NA D: 13.2% (12/91) CRO 250 mg N: 0.0% (0/104) V: NA D: 3.8% (4/104) |
| Handsfield36 | 1994 | AZM 2 g CRO 250 mg | 96.3 (26/27) 100.0 (17/17) | STI Clinic, USA | Both | Culture | 7 | AZM 2 g N: 19.5% (84/431) V: 7.0% (30/431) D: 13.7% (59/431) CRO 250 mg, NA |
| Hook39 | 1986 | SPT 2 g | 100.0 (33/33) | STI Clinic, USA | M | Culture | 5.5 | |
| Hook38 | 1993 | CIP 250 mg CRO 250 mg | 100.0 (20/20) 100.0 (21/21) | STI Clinic, USA | F | Culture | 7 | |
| Hook72 | 1997 | CFM 400 mg | 100.0 (3/3) | Hospital, country not stated | M | Culture | 7.5 | |
| Hook17 | 2019 | CRO 250 mg DEL 900 mg | 100.0 (13/13) 82.6 (19/23) | Setting not stated, USA | Both | Culture+NAAT | 7 | CRO 250 mg N: 1.3% (2/154) V: 0.6% (1/154) D: 7.1% (11/154) DEL 900 mg N: 7.9% (24/304) V: 2.6% (8/304) D: 31.9% (97/304) |
| Jones40 | 1991 | CTX 500 mg CRO 250 mg | 100.0 (5/5) 100.0 (4/4) | STI Clinic, USA | Both | Culture | 5.5 | CTX 500 mg, NA CRO 250 mg N: 1.7% (1/58) V: NA D: 3.4% (2/58) |
| Judson73 | 1983 | CRO 250 mg PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (10/10) 100.0 (11/11) | Setting and country not stated | F | Culture | 5.5 | |
| Judson41 | 1985 | CRO 125 mg SPT 2 g | 100.0 (52/52) 100.0 (9/9) | STI Clinic, USA | M | Culture | 6 | |
| Kaplowitz42 | 1987 | AMP 3.5 g+PROB 1 g | 87.5 (7/8) | STI Clinic, USA | Both | Culture | 5 | AMP 3.5 g+PROB 1 g N: 2.7% (2/75) V: 1.3% (1/75) D: NA |
| Kirkcaldy43 | 2014 | GEN 240 mg+AZM 2 g GEM 320 mg+AZM 2 g | 100.0 (1/1) 100.0 (5/5) | STI Clinic, USA | Both | Culture | 13.5 | GEN 240 mg+AZM 2 g N: 27.7% (56/202) V: 7.4% (15/202) D: 19.3% (39/202) GEM 320 mg+AZM 2 g N: 37.2% (74/199) V: 5.0% (10/199) D: 23.1% (46/199) |
| Lossick44 | 1982 | CFX 1.5 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 97.1 (34/35) 85.2 (23/27) | STI Clinic, USA | F | Culture | 5 | |
| McCormack45 | 1993 | CTX 500 mg CRO 250 mg | 100.0 (16/16) 100.0 (19/19) | Setting not stated, USA | Both | Culture | 5.5 | |
| Mogabgab46 | 1994 | CTX 500 mg CRO 250 mg | 100.0 (3/3) 100.0 (3/3) | STI Clinic, USA | Both | Culture | 5.5 | |
| Mohanty60 | 1988 | ATM 1 g | 100.0 (8/8) | Hospital, UK | Both | Culture | 14 | |
| Mroczkowski47 | 1997 | CFM 400 mg | 97.4 (37/38) | STI Clinic, USA | F | Culture | 7.5 | CFM 400 mg N: 2.1% (4/189) V: 1.1% (2/189) D: 0.5% (1/189) |
| Obaid48 | 1983 | PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Pabst49 | 1989 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 8.5 | |
| Raad58 | 1988 | PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) | STI Clinic, USA and Peru | Both | Culture | 5 | |
| Ramus50 | 2001 | CRO 125 mg CFM 400 mg | 100.0 (23/23) 100.0 (16/16) | Hospital, USA | F (pregnant females only) | Culture | 7 | |
| Rob66 | 2019 | GEN 240 mg+AZM 2 g CRO 500 mg+AZM 2 g | 100.0 (40/40) 100.0 (38/38) | Hospital, Czech Republic | Both | NAAT | 10 | GEN 240 mg+AZM 2 g N: 19.4% (14/72) V: 0.0% (0/72) D: 23.6% (17/72) CRO 500 mg+AZM 2 g N: 26.8% (19/71) V: 1.4% (1/71) D: 26.8% (19/71) |
| Romanowski65 | 1984 | AMP 3.5 g+PROB 1 g | 100.0 (23/23) | Setting not stated, Canada | Both | Culture | 5.5 | |
| Ross61 | 2019 | GEN 240 mg+AZM 1 g CRO 500 mg+AZM 1 g | 89.9 (107/119) 97.8 (134/137) | STI Clinic, UK | Both | Culture+NAAT | 14 | GEN 240 mg+AZM 1 g N: 13.8% (41/298) V: 4.0% (12/298) D: NA CRO 500 mg+AZM 1 g N: 11.9% (38/320) V: 0.9% (3/320) D: NA |
| Scott62 | 1987 | CIP 250 mg AMP 500 mg q6h for 5/7+PROB 1 g | 100.0 (3/3) 100.0 (3/3) | Hospital, UK | M | Culture | 14 | |
| Simpson51 | 1981 | PPEN 4.8 MU+PROB 1 g CTX 1 g | 100.0 (9/9) 100.0 (9/9) | STI Clinic, USA | Both | Culture | 5 | |
| Simpson52 | 1982 | PIP 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Sinanian53 | 1973 | SPT 4 g TET 9 g | 98.2 (54/55) 93.0 (53/57) | STI Clinic, USA | F | Culture | 7 | SPT 4 g, NA TET 9 g N: 3.0% (6/198) V: NA D: NA |
| Slutkin54 | 1982 | PPEN 4.8 MU+PROB 1 g | 87.5 (14/16) | STI Clinic, USA | Both | Culture | 6 | |
| Smith55 | 1993 | CRO 250 mg | 100.0 (24/24) | STI Clinic, USA | F | Culture | 7 | CRO 250 mg N: 0.3% (1/380) V: NA D: 0.5% (2/380) |
| Stolz67 | 1984 | CTX 1 g CFX 1.5 g | 100.0 (103/103) 92.2 (71/77) | Setting not stated, The Netherlands | Both | Culture | 10.5 | CTX 1 g N: 0.3% (2/590) V: NA D: NA CFX 1.5 g N: 0.3% (2/647) V: NA D: NA |
| Stoner56 | 2001 | GAT 400 mg GAT 600 mg OFX 400 mg | 100.0 (20/20) 100.0 (16/16) 100.0 (7/7) | Setting not stated, USA | F | Culture | 7 | GAT 400 mg N: 8.1% (24/295) V: 0.7% (2/295) D: 2.0% (6/295) GAT 600 mg N: 10.7% (31/291) V: 1.7% (5/291) D: 3.4% (10/291) OFX 400 mg N: 4.2% (6/142) V: 1.4% (2/142) D: 2.8% (4/142) |
| Taylor18 | 2018 | GEP 1500 mg GEP 3000 mg | 100.0 (1/1) 100.0 (2/2) | Setting not stated, USA and UK | M | Culture+NAAT | 6 | GEP 1500 mg N: 5.8% (3/52) V: NA D: 17.3% (9/52) GEP 3000 mg N: 20.8% (11/53) V: NA D: 35.8% (19/53) |
| Taylor20 | 2018 | ZOL 2 g ZOL 3 g CRO 500 mg | 100.0 (4/4) 100.0 (6/6) 100.0 (3/3) | STI Clinic, USA | Both | Culture+NAAT | 6 | |
| Thorpe57 | 1996 | CFX 1000 mg CIP 500 mg | 96.8 (30/31) 100.0 (26/26) | STI Clinic, USA and Puerto Rico | Both | Culture | 6 |
AMX, amoxicillin; AMP, ampicillin; AZM, azithromycin; ATM, aztreonam; BPEN, benzylpenicillin; CRO, ceftriaxone; CFX, cefuroxime axetil/sodium; CFM, cefixime; FOX, cefoxitin; CIP, ciprofloxacin; CTX, cefotaxime; DEL, delafloxacin; GAT, gatifloxacin; GEM, Gemifloxacin; GEN, gentamicin; GEP, gepotidacin; OFX, ofloxacin; PIP, piperacillin; PPEN, procaine penicillin; PROB, probenecid; SOL, solithromycin; SPT, spectinomycin; SUL, sulbactam; TET, tetracycline; ZOL, zoliflodacin; NA, not available.
Gender of participants in the trial who contributed to the rectal endpoint.
Side effects are nausea (N), vomiting (V) or diarrhoea (D) among all participants and not specifically among those with rectal infection.
| First author . | Publication year . | Treatment . | Percentage with rectal NG cured (no. cured/ no. tested) . | Setting and country . | Gender of participantsa . | Diagnostic assay . | Median follow up (days) . | Side effects % (no./total)b . |
|---|---|---|---|---|---|---|---|---|
| Baddour25 | 1989 | CFX 1 g AMX 3 g+PROB 1 g | 98.1 (53/54) 97.6 (41/42) | STI Clinic, USA | F | Culture | 5.5 | CFX 1 g N: 3.8% (9/235) V: 3.4% (8/235) D: 1.3% (3/235) AMX 3 g+PROB 1 g N: 2.2% (5/231) V: 0.9% (2/231) D: 3.5% (8/231) |
| Baddour24 | 1992 | AMP 1 g+SUL 0.5 g+PROB 1 g CRO 250 mg | 100.0 (8/8) 100.0 (7/7) | STI Clinic, USA | Both | Culture | 5.5 | AMP 1 g+SUL 0.5 g+PROB 1 g, NA CRO 250 mg N: NA V: NA D: 3.1% (3/97) |
| Batteiger26 | 1985 | AMP 3.5 g+PROB 1 g | 100.0 (12/12) | STI Clinic, USA | F | Culture | 10.5 | |
| Black27 | 1989 | OFX 400 mg AMX 3 g+PROB 1 g | 100.0 (13/13) 100.0 (17/17) | STI Clinic, USA | F | Culture | 7.5 | |
| Cavenee28 | 1993 | CRO 250 mg SPT 2 g AMX 3 g+PROB 1 g | 95.5 (21/22) 100.0 (19/19) 85.2 (23/27) | Hospital, USA | F (pregnant females only) | Culture | 7 | CRO 250 mg, NA SPT 2 g, NA AMX 3 g+PROB 1 g N: NA V: 1.2% (1/84) D: NA |
| Chen19 | 2019 | CRO 500 mg+AZM 1000 mg SOL 1000 mg | 100.0 (12/12) 83.3 (5/6) | STI Clinic, USA and Australia | Both | Culture+NAAT | 7 | CRO 500 mg+AZM 1000 mg N: 11.5% (15/131) V: 0.0% (0/131) D: 15.3% (20/131) SOL 1000 mg N: 20.8% (27/130) V: 2.3% (3/130) D: 23.8% (31/130) |
| Collier29 | 1984 | CRO 125 mg SPT 2 g | 100.0 (23/23) 100.0 (12/12) | STI Clinic, USA | F | Culture | 6 | |
| Covino30 | 1990 | OFX 400 mg CRO 250 mg | 100.0 (2/2) 83.3 (5/6) | STI Clinic, USA | F | Culture | 6 | |
| Covino31 | 1993 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 7 | |
| Das68 | 1989 | CFX 1 g AMP 3 g+PROB 1 g | 100.0 (7/7) 100.0 (4/4) | Setting and country not stated | Both | Culture | 7 | |
| Dixon59 | 1986 | CRO 500 mg PPEN 1.5 g+BPEN 300 mg | 100.0 (1/1) 80.0 (4/5) | STI Clinic, UK | Both | Culture | 16 | |
| Dubois69 | 1990 | AMX 3 g+PROB 1 g | 100.0 (2/2) | Setting and country not stated | F | Culture | 5.5 | AMX 3 g+PROB 1 g N: 3.9% (3/77) V: 2.6% (2/77) D: 1.3% (1/77) |
| Edwards32 | 1984 | AMX 3 g+PROB 1 g | 100.0 (7/7) | STI Clinic, USA | Both | Culture | 7 | |
| Forstrom64 | 1972 | PPEN 2.4 MU | 100.0 (14/14) | Hospital, Finland | F | Culture | 7 | |
| Forstrom63 | 1974 | AMP 2000 mg+PROB 1 g | 92.9 (13/14) | Hospital, Finland | F | Culture | 7 | |
| Gottlieb33 | 1985 | ATM 1 g SPT 2 g | 100.0 (3/3) 100.0 (6/6) | STI Clinic, USA | Both | Culture | 6 | |
| Gottlieb34 | 1986 | CFX 1 g+PROB 1 g CFX 1 g AMX 3 g+PROB 1 g | 100.0 (6/6) 66.7 (4/6) 66.7 (2/3) | STI Clinic, USA | M | Culture | 6 | |
| Greaves35 | 1983 | FOX 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 95.7 (45/47) 97.4 (38/39) | STI Clinic, USA | Both | Culture | 8 | |
| Handsfield71 | 1981 | CRO 125 mg CRO 250 mg CRO 500 mg | 100.0 (5/5) 100.0 (3/3) 100.0 (2/2) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield70 | 1983 | CRO 125 mg CRO 250 mg SPT 2 g | 100.0 (8/8) 100.0 (6/6) 95.5 (21/22) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield37 | 1991 | CFM 400 mg CFM 800 mg CRO 250 mg | 100.0 (10/10) 100.0 (6/6) 100.0 (6/6) | STI Clinic, USA | F | Culture | 6.5 | CFM 400 mg N: 0.9% (1/107) V: NA D: 7.5% (8/107) CFM 800 mg N: 4.4% (4/91) V: NA D: 13.2% (12/91) CRO 250 mg N: 0.0% (0/104) V: NA D: 3.8% (4/104) |
| Handsfield36 | 1994 | AZM 2 g CRO 250 mg | 96.3 (26/27) 100.0 (17/17) | STI Clinic, USA | Both | Culture | 7 | AZM 2 g N: 19.5% (84/431) V: 7.0% (30/431) D: 13.7% (59/431) CRO 250 mg, NA |
| Hook39 | 1986 | SPT 2 g | 100.0 (33/33) | STI Clinic, USA | M | Culture | 5.5 | |
| Hook38 | 1993 | CIP 250 mg CRO 250 mg | 100.0 (20/20) 100.0 (21/21) | STI Clinic, USA | F | Culture | 7 | |
| Hook72 | 1997 | CFM 400 mg | 100.0 (3/3) | Hospital, country not stated | M | Culture | 7.5 | |
| Hook17 | 2019 | CRO 250 mg DEL 900 mg | 100.0 (13/13) 82.6 (19/23) | Setting not stated, USA | Both | Culture+NAAT | 7 | CRO 250 mg N: 1.3% (2/154) V: 0.6% (1/154) D: 7.1% (11/154) DEL 900 mg N: 7.9% (24/304) V: 2.6% (8/304) D: 31.9% (97/304) |
| Jones40 | 1991 | CTX 500 mg CRO 250 mg | 100.0 (5/5) 100.0 (4/4) | STI Clinic, USA | Both | Culture | 5.5 | CTX 500 mg, NA CRO 250 mg N: 1.7% (1/58) V: NA D: 3.4% (2/58) |
| Judson73 | 1983 | CRO 250 mg PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (10/10) 100.0 (11/11) | Setting and country not stated | F | Culture | 5.5 | |
| Judson41 | 1985 | CRO 125 mg SPT 2 g | 100.0 (52/52) 100.0 (9/9) | STI Clinic, USA | M | Culture | 6 | |
| Kaplowitz42 | 1987 | AMP 3.5 g+PROB 1 g | 87.5 (7/8) | STI Clinic, USA | Both | Culture | 5 | AMP 3.5 g+PROB 1 g N: 2.7% (2/75) V: 1.3% (1/75) D: NA |
| Kirkcaldy43 | 2014 | GEN 240 mg+AZM 2 g GEM 320 mg+AZM 2 g | 100.0 (1/1) 100.0 (5/5) | STI Clinic, USA | Both | Culture | 13.5 | GEN 240 mg+AZM 2 g N: 27.7% (56/202) V: 7.4% (15/202) D: 19.3% (39/202) GEM 320 mg+AZM 2 g N: 37.2% (74/199) V: 5.0% (10/199) D: 23.1% (46/199) |
| Lossick44 | 1982 | CFX 1.5 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 97.1 (34/35) 85.2 (23/27) | STI Clinic, USA | F | Culture | 5 | |
| McCormack45 | 1993 | CTX 500 mg CRO 250 mg | 100.0 (16/16) 100.0 (19/19) | Setting not stated, USA | Both | Culture | 5.5 | |
| Mogabgab46 | 1994 | CTX 500 mg CRO 250 mg | 100.0 (3/3) 100.0 (3/3) | STI Clinic, USA | Both | Culture | 5.5 | |
| Mohanty60 | 1988 | ATM 1 g | 100.0 (8/8) | Hospital, UK | Both | Culture | 14 | |
| Mroczkowski47 | 1997 | CFM 400 mg | 97.4 (37/38) | STI Clinic, USA | F | Culture | 7.5 | CFM 400 mg N: 2.1% (4/189) V: 1.1% (2/189) D: 0.5% (1/189) |
| Obaid48 | 1983 | PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Pabst49 | 1989 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 8.5 | |
| Raad58 | 1988 | PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) | STI Clinic, USA and Peru | Both | Culture | 5 | |
| Ramus50 | 2001 | CRO 125 mg CFM 400 mg | 100.0 (23/23) 100.0 (16/16) | Hospital, USA | F (pregnant females only) | Culture | 7 | |
| Rob66 | 2019 | GEN 240 mg+AZM 2 g CRO 500 mg+AZM 2 g | 100.0 (40/40) 100.0 (38/38) | Hospital, Czech Republic | Both | NAAT | 10 | GEN 240 mg+AZM 2 g N: 19.4% (14/72) V: 0.0% (0/72) D: 23.6% (17/72) CRO 500 mg+AZM 2 g N: 26.8% (19/71) V: 1.4% (1/71) D: 26.8% (19/71) |
| Romanowski65 | 1984 | AMP 3.5 g+PROB 1 g | 100.0 (23/23) | Setting not stated, Canada | Both | Culture | 5.5 | |
| Ross61 | 2019 | GEN 240 mg+AZM 1 g CRO 500 mg+AZM 1 g | 89.9 (107/119) 97.8 (134/137) | STI Clinic, UK | Both | Culture+NAAT | 14 | GEN 240 mg+AZM 1 g N: 13.8% (41/298) V: 4.0% (12/298) D: NA CRO 500 mg+AZM 1 g N: 11.9% (38/320) V: 0.9% (3/320) D: NA |
| Scott62 | 1987 | CIP 250 mg AMP 500 mg q6h for 5/7+PROB 1 g | 100.0 (3/3) 100.0 (3/3) | Hospital, UK | M | Culture | 14 | |
| Simpson51 | 1981 | PPEN 4.8 MU+PROB 1 g CTX 1 g | 100.0 (9/9) 100.0 (9/9) | STI Clinic, USA | Both | Culture | 5 | |
| Simpson52 | 1982 | PIP 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Sinanian53 | 1973 | SPT 4 g TET 9 g | 98.2 (54/55) 93.0 (53/57) | STI Clinic, USA | F | Culture | 7 | SPT 4 g, NA TET 9 g N: 3.0% (6/198) V: NA D: NA |
| Slutkin54 | 1982 | PPEN 4.8 MU+PROB 1 g | 87.5 (14/16) | STI Clinic, USA | Both | Culture | 6 | |
| Smith55 | 1993 | CRO 250 mg | 100.0 (24/24) | STI Clinic, USA | F | Culture | 7 | CRO 250 mg N: 0.3% (1/380) V: NA D: 0.5% (2/380) |
| Stolz67 | 1984 | CTX 1 g CFX 1.5 g | 100.0 (103/103) 92.2 (71/77) | Setting not stated, The Netherlands | Both | Culture | 10.5 | CTX 1 g N: 0.3% (2/590) V: NA D: NA CFX 1.5 g N: 0.3% (2/647) V: NA D: NA |
| Stoner56 | 2001 | GAT 400 mg GAT 600 mg OFX 400 mg | 100.0 (20/20) 100.0 (16/16) 100.0 (7/7) | Setting not stated, USA | F | Culture | 7 | GAT 400 mg N: 8.1% (24/295) V: 0.7% (2/295) D: 2.0% (6/295) GAT 600 mg N: 10.7% (31/291) V: 1.7% (5/291) D: 3.4% (10/291) OFX 400 mg N: 4.2% (6/142) V: 1.4% (2/142) D: 2.8% (4/142) |
| Taylor18 | 2018 | GEP 1500 mg GEP 3000 mg | 100.0 (1/1) 100.0 (2/2) | Setting not stated, USA and UK | M | Culture+NAAT | 6 | GEP 1500 mg N: 5.8% (3/52) V: NA D: 17.3% (9/52) GEP 3000 mg N: 20.8% (11/53) V: NA D: 35.8% (19/53) |
| Taylor20 | 2018 | ZOL 2 g ZOL 3 g CRO 500 mg | 100.0 (4/4) 100.0 (6/6) 100.0 (3/3) | STI Clinic, USA | Both | Culture+NAAT | 6 | |
| Thorpe57 | 1996 | CFX 1000 mg CIP 500 mg | 96.8 (30/31) 100.0 (26/26) | STI Clinic, USA and Puerto Rico | Both | Culture | 6 |
| First author . | Publication year . | Treatment . | Percentage with rectal NG cured (no. cured/ no. tested) . | Setting and country . | Gender of participantsa . | Diagnostic assay . | Median follow up (days) . | Side effects % (no./total)b . |
|---|---|---|---|---|---|---|---|---|
| Baddour25 | 1989 | CFX 1 g AMX 3 g+PROB 1 g | 98.1 (53/54) 97.6 (41/42) | STI Clinic, USA | F | Culture | 5.5 | CFX 1 g N: 3.8% (9/235) V: 3.4% (8/235) D: 1.3% (3/235) AMX 3 g+PROB 1 g N: 2.2% (5/231) V: 0.9% (2/231) D: 3.5% (8/231) |
| Baddour24 | 1992 | AMP 1 g+SUL 0.5 g+PROB 1 g CRO 250 mg | 100.0 (8/8) 100.0 (7/7) | STI Clinic, USA | Both | Culture | 5.5 | AMP 1 g+SUL 0.5 g+PROB 1 g, NA CRO 250 mg N: NA V: NA D: 3.1% (3/97) |
| Batteiger26 | 1985 | AMP 3.5 g+PROB 1 g | 100.0 (12/12) | STI Clinic, USA | F | Culture | 10.5 | |
| Black27 | 1989 | OFX 400 mg AMX 3 g+PROB 1 g | 100.0 (13/13) 100.0 (17/17) | STI Clinic, USA | F | Culture | 7.5 | |
| Cavenee28 | 1993 | CRO 250 mg SPT 2 g AMX 3 g+PROB 1 g | 95.5 (21/22) 100.0 (19/19) 85.2 (23/27) | Hospital, USA | F (pregnant females only) | Culture | 7 | CRO 250 mg, NA SPT 2 g, NA AMX 3 g+PROB 1 g N: NA V: 1.2% (1/84) D: NA |
| Chen19 | 2019 | CRO 500 mg+AZM 1000 mg SOL 1000 mg | 100.0 (12/12) 83.3 (5/6) | STI Clinic, USA and Australia | Both | Culture+NAAT | 7 | CRO 500 mg+AZM 1000 mg N: 11.5% (15/131) V: 0.0% (0/131) D: 15.3% (20/131) SOL 1000 mg N: 20.8% (27/130) V: 2.3% (3/130) D: 23.8% (31/130) |
| Collier29 | 1984 | CRO 125 mg SPT 2 g | 100.0 (23/23) 100.0 (12/12) | STI Clinic, USA | F | Culture | 6 | |
| Covino30 | 1990 | OFX 400 mg CRO 250 mg | 100.0 (2/2) 83.3 (5/6) | STI Clinic, USA | F | Culture | 6 | |
| Covino31 | 1993 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 7 | |
| Das68 | 1989 | CFX 1 g AMP 3 g+PROB 1 g | 100.0 (7/7) 100.0 (4/4) | Setting and country not stated | Both | Culture | 7 | |
| Dixon59 | 1986 | CRO 500 mg PPEN 1.5 g+BPEN 300 mg | 100.0 (1/1) 80.0 (4/5) | STI Clinic, UK | Both | Culture | 16 | |
| Dubois69 | 1990 | AMX 3 g+PROB 1 g | 100.0 (2/2) | Setting and country not stated | F | Culture | 5.5 | AMX 3 g+PROB 1 g N: 3.9% (3/77) V: 2.6% (2/77) D: 1.3% (1/77) |
| Edwards32 | 1984 | AMX 3 g+PROB 1 g | 100.0 (7/7) | STI Clinic, USA | Both | Culture | 7 | |
| Forstrom64 | 1972 | PPEN 2.4 MU | 100.0 (14/14) | Hospital, Finland | F | Culture | 7 | |
| Forstrom63 | 1974 | AMP 2000 mg+PROB 1 g | 92.9 (13/14) | Hospital, Finland | F | Culture | 7 | |
| Gottlieb33 | 1985 | ATM 1 g SPT 2 g | 100.0 (3/3) 100.0 (6/6) | STI Clinic, USA | Both | Culture | 6 | |
| Gottlieb34 | 1986 | CFX 1 g+PROB 1 g CFX 1 g AMX 3 g+PROB 1 g | 100.0 (6/6) 66.7 (4/6) 66.7 (2/3) | STI Clinic, USA | M | Culture | 6 | |
| Greaves35 | 1983 | FOX 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 95.7 (45/47) 97.4 (38/39) | STI Clinic, USA | Both | Culture | 8 | |
| Handsfield71 | 1981 | CRO 125 mg CRO 250 mg CRO 500 mg | 100.0 (5/5) 100.0 (3/3) 100.0 (2/2) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield70 | 1983 | CRO 125 mg CRO 250 mg SPT 2 g | 100.0 (8/8) 100.0 (6/6) 95.5 (21/22) | STI Clinic, country not stated | M | Culture | 5.5 | |
| Handsfield37 | 1991 | CFM 400 mg CFM 800 mg CRO 250 mg | 100.0 (10/10) 100.0 (6/6) 100.0 (6/6) | STI Clinic, USA | F | Culture | 6.5 | CFM 400 mg N: 0.9% (1/107) V: NA D: 7.5% (8/107) CFM 800 mg N: 4.4% (4/91) V: NA D: 13.2% (12/91) CRO 250 mg N: 0.0% (0/104) V: NA D: 3.8% (4/104) |
| Handsfield36 | 1994 | AZM 2 g CRO 250 mg | 96.3 (26/27) 100.0 (17/17) | STI Clinic, USA | Both | Culture | 7 | AZM 2 g N: 19.5% (84/431) V: 7.0% (30/431) D: 13.7% (59/431) CRO 250 mg, NA |
| Hook39 | 1986 | SPT 2 g | 100.0 (33/33) | STI Clinic, USA | M | Culture | 5.5 | |
| Hook38 | 1993 | CIP 250 mg CRO 250 mg | 100.0 (20/20) 100.0 (21/21) | STI Clinic, USA | F | Culture | 7 | |
| Hook72 | 1997 | CFM 400 mg | 100.0 (3/3) | Hospital, country not stated | M | Culture | 7.5 | |
| Hook17 | 2019 | CRO 250 mg DEL 900 mg | 100.0 (13/13) 82.6 (19/23) | Setting not stated, USA | Both | Culture+NAAT | 7 | CRO 250 mg N: 1.3% (2/154) V: 0.6% (1/154) D: 7.1% (11/154) DEL 900 mg N: 7.9% (24/304) V: 2.6% (8/304) D: 31.9% (97/304) |
| Jones40 | 1991 | CTX 500 mg CRO 250 mg | 100.0 (5/5) 100.0 (4/4) | STI Clinic, USA | Both | Culture | 5.5 | CTX 500 mg, NA CRO 250 mg N: 1.7% (1/58) V: NA D: 3.4% (2/58) |
| Judson73 | 1983 | CRO 250 mg PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (10/10) 100.0 (11/11) | Setting and country not stated | F | Culture | 5.5 | |
| Judson41 | 1985 | CRO 125 mg SPT 2 g | 100.0 (52/52) 100.0 (9/9) | STI Clinic, USA | M | Culture | 6 | |
| Kaplowitz42 | 1987 | AMP 3.5 g+PROB 1 g | 87.5 (7/8) | STI Clinic, USA | Both | Culture | 5 | AMP 3.5 g+PROB 1 g N: 2.7% (2/75) V: 1.3% (1/75) D: NA |
| Kirkcaldy43 | 2014 | GEN 240 mg+AZM 2 g GEM 320 mg+AZM 2 g | 100.0 (1/1) 100.0 (5/5) | STI Clinic, USA | Both | Culture | 13.5 | GEN 240 mg+AZM 2 g N: 27.7% (56/202) V: 7.4% (15/202) D: 19.3% (39/202) GEM 320 mg+AZM 2 g N: 37.2% (74/199) V: 5.0% (10/199) D: 23.1% (46/199) |
| Lossick44 | 1982 | CFX 1.5 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 97.1 (34/35) 85.2 (23/27) | STI Clinic, USA | F | Culture | 5 | |
| McCormack45 | 1993 | CTX 500 mg CRO 250 mg | 100.0 (16/16) 100.0 (19/19) | Setting not stated, USA | Both | Culture | 5.5 | |
| Mogabgab46 | 1994 | CTX 500 mg CRO 250 mg | 100.0 (3/3) 100.0 (3/3) | STI Clinic, USA | Both | Culture | 5.5 | |
| Mohanty60 | 1988 | ATM 1 g | 100.0 (8/8) | Hospital, UK | Both | Culture | 14 | |
| Mroczkowski47 | 1997 | CFM 400 mg | 97.4 (37/38) | STI Clinic, USA | F | Culture | 7.5 | CFM 400 mg N: 2.1% (4/189) V: 1.1% (2/189) D: 0.5% (1/189) |
| Obaid48 | 1983 | PPEN 4.8 MU (×2 doses)+PROB 1 g | 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Pabst49 | 1989 | CRO 250 mg | 100.0 (5/5) | STI Clinic, USA | Both | Culture | 8.5 | |
| Raad58 | 1988 | PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) | STI Clinic, USA and Peru | Both | Culture | 5 | |
| Ramus50 | 2001 | CRO 125 mg CFM 400 mg | 100.0 (23/23) 100.0 (16/16) | Hospital, USA | F (pregnant females only) | Culture | 7 | |
| Rob66 | 2019 | GEN 240 mg+AZM 2 g CRO 500 mg+AZM 2 g | 100.0 (40/40) 100.0 (38/38) | Hospital, Czech Republic | Both | NAAT | 10 | GEN 240 mg+AZM 2 g N: 19.4% (14/72) V: 0.0% (0/72) D: 23.6% (17/72) CRO 500 mg+AZM 2 g N: 26.8% (19/71) V: 1.4% (1/71) D: 26.8% (19/71) |
| Romanowski65 | 1984 | AMP 3.5 g+PROB 1 g | 100.0 (23/23) | Setting not stated, Canada | Both | Culture | 5.5 | |
| Ross61 | 2019 | GEN 240 mg+AZM 1 g CRO 500 mg+AZM 1 g | 89.9 (107/119) 97.8 (134/137) | STI Clinic, UK | Both | Culture+NAAT | 14 | GEN 240 mg+AZM 1 g N: 13.8% (41/298) V: 4.0% (12/298) D: NA CRO 500 mg+AZM 1 g N: 11.9% (38/320) V: 0.9% (3/320) D: NA |
| Scott62 | 1987 | CIP 250 mg AMP 500 mg q6h for 5/7+PROB 1 g | 100.0 (3/3) 100.0 (3/3) | Hospital, UK | M | Culture | 14 | |
| Simpson51 | 1981 | PPEN 4.8 MU+PROB 1 g CTX 1 g | 100.0 (9/9) 100.0 (9/9) | STI Clinic, USA | Both | Culture | 5 | |
| Simpson52 | 1982 | PIP 2 g+PROB 1 g PPEN 4.8 MU+PROB 1 g | 100.0 (1/1) 100.0 (4/4) | STI Clinic, USA | M | Culture | 5 | |
| Sinanian53 | 1973 | SPT 4 g TET 9 g | 98.2 (54/55) 93.0 (53/57) | STI Clinic, USA | F | Culture | 7 | SPT 4 g, NA TET 9 g N: 3.0% (6/198) V: NA D: NA |
| Slutkin54 | 1982 | PPEN 4.8 MU+PROB 1 g | 87.5 (14/16) | STI Clinic, USA | Both | Culture | 6 | |
| Smith55 | 1993 | CRO 250 mg | 100.0 (24/24) | STI Clinic, USA | F | Culture | 7 | CRO 250 mg N: 0.3% (1/380) V: NA D: 0.5% (2/380) |
| Stolz67 | 1984 | CTX 1 g CFX 1.5 g | 100.0 (103/103) 92.2 (71/77) | Setting not stated, The Netherlands | Both | Culture | 10.5 | CTX 1 g N: 0.3% (2/590) V: NA D: NA CFX 1.5 g N: 0.3% (2/647) V: NA D: NA |
| Stoner56 | 2001 | GAT 400 mg GAT 600 mg OFX 400 mg | 100.0 (20/20) 100.0 (16/16) 100.0 (7/7) | Setting not stated, USA | F | Culture | 7 | GAT 400 mg N: 8.1% (24/295) V: 0.7% (2/295) D: 2.0% (6/295) GAT 600 mg N: 10.7% (31/291) V: 1.7% (5/291) D: 3.4% (10/291) OFX 400 mg N: 4.2% (6/142) V: 1.4% (2/142) D: 2.8% (4/142) |
| Taylor18 | 2018 | GEP 1500 mg GEP 3000 mg | 100.0 (1/1) 100.0 (2/2) | Setting not stated, USA and UK | M | Culture+NAAT | 6 | GEP 1500 mg N: 5.8% (3/52) V: NA D: 17.3% (9/52) GEP 3000 mg N: 20.8% (11/53) V: NA D: 35.8% (19/53) |
| Taylor20 | 2018 | ZOL 2 g ZOL 3 g CRO 500 mg | 100.0 (4/4) 100.0 (6/6) 100.0 (3/3) | STI Clinic, USA | Both | Culture+NAAT | 6 | |
| Thorpe57 | 1996 | CFX 1000 mg CIP 500 mg | 96.8 (30/31) 100.0 (26/26) | STI Clinic, USA and Puerto Rico | Both | Culture | 6 |
AMX, amoxicillin; AMP, ampicillin; AZM, azithromycin; ATM, aztreonam; BPEN, benzylpenicillin; CRO, ceftriaxone; CFX, cefuroxime axetil/sodium; CFM, cefixime; FOX, cefoxitin; CIP, ciprofloxacin; CTX, cefotaxime; DEL, delafloxacin; GAT, gatifloxacin; GEM, Gemifloxacin; GEN, gentamicin; GEP, gepotidacin; OFX, ofloxacin; PIP, piperacillin; PPEN, procaine penicillin; PROB, probenecid; SOL, solithromycin; SPT, spectinomycin; SUL, sulbactam; TET, tetracycline; ZOL, zoliflodacin; NA, not available.
Gender of participants in the trial who contributed to the rectal endpoint.
Side effects are nausea (N), vomiting (V) or diarrhoea (D) among all participants and not specifically among those with rectal infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
